Evidence map›Paper›PMID 20443837›Full record

ArticleClinical and translational science2008

Sex modulates intestinal transformation by the tumor-suppressor GCC.

Peng Li, Stephanie Schulz, Giovanni M Pitari, Scott A Waldman

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and translational science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Peng LiDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Peng.Li@jefferson.edu <Peng.Li@jefferson.edu>
Stephanie Schulz
Giovanni M Pitari
Scott A Waldman
Thomas Jefferson University · US

Funding

Guanylyl Cyclase C in Blood and Colorectal CancerR01CA095026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2003 to 2008
$5.1M
GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCERR01CA075123 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A. · 1998 to 2006
$5.1M
NCI NIH HHS CA75123NCI NIH HHS CA95026NCI NIH HHS R01 CA075123NCI NIH HHS R01 CA095026
6 · The paper itself

Abstract

BACKGROUND AND

aimsOvarian hormones oppose colorectal cancer, although mechanisms remain undefined. Similarly, the most commonly lost gene products in intestinal neoplasia include guanylin and uroguanylin, paracrine hormones for guanylyl cyclase C (GCC), which recently emerged as a tumor suppressor. However, the molecular intersection between intestinal paracrine and systemic sex hormones opposing intestinal neoplasia has not been explored.

methodsIntestinal tumorigenesis was quantified in wild type (Gcc(+/+)) and GCC-deficient (Gcc(-/-)) mice carrying mutations in adenomatous polyposis coli (Apc) (Apc(Min/+)) or exposed to the carcinogen azoxymethane (AOM). Proliferation of epithelial cells was examined employing cell cycle markers.

resultsDeletion of Gcc increased tumor multiplicity and growth in colons and small intestines, respectively, of Apc(Min) (/+) mice. While changes in multiplicity and growth increased tumor burden, females exhibited approximately 60% (p= 0.040) of the burden in males. Similarly, female Gcc(-/-) mice treated with AOM exhibited approximately 40% (p= 0.048) of the burden in males. Moreover, Gcc deletion promoted epithelial cell proliferation, quantified by increases in beta-catenin, cMyc, cyclin D1, and phosphorylated retinoblastoma protein (pRb), in males but not females.

conclusionThere is a previously unappreciated interaction between sex and GCC signaling restricting crypt cell proliferation. Thus, the invariable loss of guanylin and uroguanylin resulting in tumorigenesis is mitigated in females by hormonal components of the ovarian axis. In the context of the universal overexpression of GCC by tumors, these observations highlight the combination of GCC paracrine and ovarian hormones for targeted prevention and therapy of colorectal cancer.

Indexed as

Sex CharacteristicsAdenomatous Polyposis Coli ProteinAnimalsAzoxymethaneCell ProliferationCell Transformation, NeoplasticColorectal NeoplasmsEnterocytesFemaleGuanylate CyclaseIntestinesMaleMiceReceptors, EnterotoxinReceptors, Guanylate Cyclase-CoupledReceptors, PeptideAdenomatous Polyposis Coli ProteinAzoxymethaneGuanylate CyclaseReceptors, EnterotoxinReceptors, Guanylate Cyclase-CoupledReceptors, PeptideTumor Suppressor Proteins

Identifiers

PMID20443837
PMCPMC4406767
OpenAlexW4239883139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.